Forus Stock
| Valuation | $3B1 |
| Valuation Date | Sep 8, 2026 |
| Implied Valuation | n/a |
| Last Price | n/a |
| 52-Week High | n/a |
| 52-Week Low | n/a |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $310M2 |
| Latest Round Amount | $150M1 |
| Latest Round | Series C |
| Funding Rounds | 4 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Forus
Forus is a healthcare technology company that uses AI to help patients get onto the medications their doctors prescribe. Its platform connects doctors, pharmacies, insurers and biopharma companies. It gives each prescription an AI agent that works through insurance authorizations, financial assistance and pharmacy fulfillment. The company says this cuts approvals that once took months down to a couple of days. Its network reaches patients across all 50 states. Forus makes money by charging biopharmaceutical manufacturers while keeping the product free for doctors and patients. The company was founded in 2023 as Tandem by Sahir Jaggi, who previously spent several years at the insurer Oscar Health, and rebranded to Forus in 2026.
Invest in Forus
Forus is a private company, so you can't purchase it with a regular brokerage account. However, the company is listed on Forge.
Forge is a trusted platform for transactions of shares of private companies. It is a subsidiary of The Charles Schwab Corporation.
Invest on ForgeDisclosure: Stock Analysis may be compensated for user sign-ups through Forge links.
Related Companies
News
Forus Secures $150M Series C, Reaches $3B Valuation
MedCity News covered Forus's Series C to expand its AI platform connecting doctors, pharmacies, payers, and biopharma across prescription workflows.
Forus Raises $150M Series C to Make Science the Only Limit on Medicine
Forus announced $150 million in Series C financing at a $3 billion valuation to expand its AI medication-access platform to every doctor's office in America.
AI healthcare platform Forus valued at $3 billion in latest funding round
Forus raised $150 million in a Series C round led by Bain Capital Ventures that valued the AI medication-access company at $3 billion, roughly tripling its valuation in about four months. The round br...
Forus, American Gastroenterological Association ink partnership
Forus announced a strategic partnership with the American Gastroenterological Association to improve medication access for patients with digestive diseases. The deal pairs the society's clinical guida...
Forus Raises $160M to Build the Foundation for Modern Medicine
Forus, formerly Tandem, raised over $160 million at a $1 billion valuation from Thrive Capital, General Catalyst, Accel, and other investors.
Billions In Prescriptions Go Unfilled. This Startup Is Using AI To Fix That.
Forus, previously known as Tandem, unveiled its new brand and said it had reached a $1 billion valuation on $160 million in total funding from investors including Thrive Capital, General Catalyst and ...
OpenEvidence and Forus partner to streamline evidence-based prescribing and prior authorizations
Forus announced a strategic partnership with OpenEvidence, an AI clinical decision-support platform, to connect evidence-based prescribing with automated prior authorization and pharmacy routing. Open...